Charles River Laboratories Navigates Mixed Quarter, Eyes Growth in 2026
CHARLES RIVER LABORATORIES (NYSE:CRL) reported financial results for the fourth quarter and full year of 2025, delivering a performance that narrowly surpassed analyst expectations on the bottom line while revenue came in slightly below forecasts. The market's initial reaction appears muted, reflecting a complex quarter marked by significant non-cash charges and a cautiously optimistic outlook for the year ahead.
Earnings and Revenue Versus Estimates
The preclinical research services provider posted fourth-quarter revenue of $994.2 million, a marginal decrease of 0.8% from the same period in 2024. This figure fell short of the Wall Street consensus estimate of approximately $996.9 million. On an organic basis, which adjusts for foreign currency and divestitures, revenue declined by 2.6%.
The company’s profitability, as measured by non-GAAP earnings per share (EPS), presented a brighter spot. Charles River reported Q4 non-GAAP EPS of $2.39, which edged out the analyst estimate of $2.37. This beat was achieved despite a 10.2% decline from the $2.66 per share reported in Q4 2024.
The divergence between the top and bottom-line performance relative to estimates highlights the challenging operating environment, but also the company's ability to manage costs. For the full year 2025, revenue was $4.02 billion, a decrease of 0.9%, while non-GAAP EPS was $10.28, essentially flat compared to 2024's $10.32.
Market Reaction and Segment Performance
The stock's performance in recent weeks has been negative, with shares down over 27% in the past month leading into the earnings release. The pre-market trading following the report showed a slight uptick of less than 1%, suggesting investors are digesting the mixed results and looking toward the company's future guidance.
A deeper look at the quarterly segment results reveals the pressures and pockets of strength:
- Discovery and Safety Assessment (DSA): Revenue of $591.6 million decreased 2.0% year-over-year. Management noted a substantial improvement in net bookings during the quarter, which they believe signals a stabilization in biopharmaceutical client demand.
- Manufacturing Solutions: Revenue was essentially flat at $196.4 million. This segment's GAAP results were heavily impacted by a combined $376 million in non-cash goodwill and intangible asset impairments related to the Biologics Solutions business. On a non-GAAP basis, however, the operating margin improved to 32.1% from 28.7%, driven by cost-saving initiatives.
- Research Models and Services (RMS): Revenue saw a slight increase of 1.0% to $206.3 million.
2026 Guidance and Analyst Expectations
Management provided financial guidance for 2026, projecting a return to organic revenue growth in the second half of the year, fueled by improved bookings in the DSA segment. The company expects reported revenue to be at least flat to up 1.5%.
The guidance for non-GAAP EPS is set between $10.70 and $11.20, representing growth of approximately 4% to 9% over 2025. This forecast is driven by cost savings from restructuring, benefits from a recent acquisition, and a lower tax rate.
Comparing this outlook to existing analyst projections provides context:
- Full-Year 2026 Revenue: Company guidance implies a range around $4.02 billion to $4.08 billion. This is notably below the current analyst sales estimate of $4.12 billion.
- Full-Year 2026 EPS: The company's non-GAAP EPS guidance range has a midpoint of $10.95. This is above the current analyst EPS estimate of $10.99 for the year, suggesting management's profit growth expectations may be more robust than the Street's revenue-driven models.
Strategic Outlook and Conclusion
Chairman, President, and CEO James C. Foster struck a tone of "cautious optimism," pointing to stabilizing demand and strategic progress. The company is focusing on efficiency improvements, selective acquisitions, and organizational refinement to position itself for a recovery in biopharma spending.
The quarterly results underscore a company in transition, managing through a sector-wide soft patch while taking painful but necessary impairment charges. The marginal EPS beat and the promise of profit growth in 2026 appear to be balancing concerns over the revenue miss and a conservative sales outlook for the coming year. Investors will likely focus on the sequential improvement in DSA bookings as the key indicator for a sustained turnaround.
For a detailed look at historical earnings and future analyst estimates for Charles River Laboratories, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any security. Investing involves risk, including the potential loss of principal.